Keros Therapeutics, Inc. (KROS)

From the record

Keros Therapeutics, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Keros Therapeutics, Inc.'s 7 filed years say what it did: revenue went from $10 million in fiscal 2019 to $244 million in fiscal 2025, up 70.3% a year; it rose in 2 of 4 years; the deepest fall was 100% from fiscal 2019 to fiscal 2020; net income was positive in 1 of 7 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Keros Therapeutics, Inc. earned about 29 cents of profit for every dollar of shareholders' money. Leverage: it owed about 10 cents per dollar of assets, and net share issuance: its share count grew 1.1% over the year (the filed statements).

From the record

Keros Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $244 million in fiscal 2025 ranks in the top 26% by size; a net margin of 35.7% ranks in the top 7% (its annual reports).

From the record

Keros Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Seehra, Jasbir (CHIEF EXECUTIVE OFFICER, as filed), filing under that title since 2020-04-07, 6.6 years (top 31% of its family); the 15 officers and directors filing in the last fifteen months have been on the record a median of 5.9 years (top 44%); 10 officer or director changes were reported on Form 8-K since 2023-11-13, against the 15 people in charge now (bottom 28%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Keros Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $289 million against no long-term debt tagged leaves 85.5% of its assets as net cash, top 14% of its family; cash from operations less capital spending is 43.4% of revenue (top 4%); research spending of 53.1% of revenue (bottom 43%) (its annual report).

From the record

Keros Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: the newest year grew 6794.9% (top 1%); research spending grew 14.1% a year (top 33%); capital spending grew 7.7% a year (top 31%) (its annual reports). Keros Therapeutics, Inc. reported 2 product lines in fiscal 2025: License at $205 million (84%), Service Other at $39 million (16%); 2 of 2 grew against the year before (its annual report).

From the record

Keros Therapeutics, Inc.'s newest year against its own record: net income of $87 million against a prior three-year average of $148 million (top 9%); a net margin of 35.7% against losses larger than its revenue before (top 2%) (its annual reports).